This Plain Language Summary of Publication article (PLSP) from Future Cardiology interviewed 26 patients and 18 doctors about a single-pill combination therapy for pulmonary arterial hypertension (PAH), a severe lung condition. The therapy combines two PAH medications (macitentan and tadalafil) and is now approved in several countries. During the 16-week study, patients received either individual medications or the combination (all taking 4 pills daily, some placebo, to prevent bias).

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Single‑Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study of the A DUE Phase 3 Trial’ and was published in Advance Therapy.

Visit Springer using the link to read the original article.